SCHEMBL831066

SCHEMBL831066

COC(=O)C(C)Oc1ccc(N=C=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ALDH2 P05091 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 3/20 0.40
TSHR P16473 2/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KLK7 P49862 1/20 0.40
LMNA P02545 2/20 0.39
CYP1A2 P05177 1/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16261973 0.87 TDP1 (0.41) KMT2AMEN1MAPTL3MBTL1TAS1R3
SCHEMBL831494 0.86 L3MBTL1 (0.43) KMT2AMAPTL3MBTL1TAS1R3TAS1R1
SCHEMBL4250581 0.84 KMT2A (0.58) KMT2AMEN1MAPTL3MBTL1ALDH2
SCHEMBL14607276 0.83 KMT2A (0.49) KMT2AMEN1MAPTL3MBTL1ALDH2
SCHEMBL16262350 0.82 GAA (0.46) KMT2AMAPTL3MBTL1TAS1R3TAS1R1
SCHEMBL10440379 0.80 TRPA1 (0.45) KMT2AMEN1MAPTL3MBTL1ALDH2
SCHEMBL11402555 0.79 TAS1R3 (0.65) KMT2AMEN1MAPTL3MBTL1ALDH2
SCHEMBL9063033 0.79 CYP1A2 (0.59) KMT2AMEN1MAPTL3MBTL1ALDH2
SCHEMBL16728392 0.79 TAS1R3 (0.65) KMT2AMEN1MAPTL3MBTL1ALDH2
SCHEMBL16270231 0.79 TDP1 (0.37) KMT2AMEN1MAPTL3MBTL1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-8846845-B2 Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices BEZWADA BIOMEDICAL, LLC (US) 2014-09-30 US disclosed
US-8846845-B2 Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices BEZWADA BIOMEDICAL, LLC (US) 2014-09-30 US disclosed
EP-2298235-B1 Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices BEZWADA BIOMEDICAL LLC (US) 2013-11-06 EP disclosed
EP-2298235-B1 Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices BEZWADA BIOMEDICAL LLC (US) 2013-11-06 EP disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-20120158127-A1 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES BEZWADA BIOMEDICAL, LLC (US) 2012-06-21 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
EP-1937182-A4 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES BEZWADA BIOMEDICAL LLC (US) 2009-07-15 EP disclosed
EP-1937182-A2 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES Bezwada Biomedical LLC (US) 2008-07-02 EP disclosed
EP-1931334-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM Bezwada Biomedical LLC (US) 2008-06-18 EP disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030464-A2 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
US-20060188547-A1 Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices BEZWADA BIOMEDICAL, LLC (US) 2006-08-24 US disclosed
US-20060172983-A1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120158127-A1 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES HAO2, AOC2, AOC1 KMT2A 650/4885MEN1 2413/4885MAPT 2702/4885
US-20060172983-A1 Functionalized drugs and polymers derived therefrom OGFR, LOX, OPRM1 KMT2A 3676/4885MEN1 4307/4885MAPT 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.